The findings, published in the American Journal of Psychiatry, were the result of a small clinical trial led by researchers at the University of Colorado Anschutz Medical Campus.
WHO issued a global safety alert last June while India's drug regulator is yet to issue a comparable advisory. US FDA has also not added a black box warning yet.
Global media also writes on failure of cloud-seeding in Delhi and the increasing demand for weight-loss drugs. FT interviews Sumant Sinha, founder of ReNew Energy.
Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.
India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.
Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to transform access to weight-loss treatment.
In a seminal work, former military officers Lt. Gen. D.S. Hooda & Lt. Col. Pavithran Rajan put forth a framework to approach cognitive warfare, called Socio-Technical-Cognitive Battlespace.
India, China and Russia share more contradictions than congruence. Each has a different worldview, as also a different adversary. The rude fact is that BRICS is the most irrelevant of all such groupings.
COMMENTS